| 000 | 01270 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250512080943.0 | ||
| 264 | 0 | _c19851114 | |
| 008 | 198511s 0 0 eng d | ||
| 022 | _a0090-4295 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZincke, H | |
| 245 | 0 | 0 |
_aReview of Mayo Clinic experience with carcinoma in situ. _h[electronic resource] |
| 260 |
_bUrology _cOct 1985 |
||
| 300 |
_a39-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Topical |
| 650 | 0 | 4 |
_aBCG Vaccine _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma in Situ _xdrug therapy |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aHematoporphyrins _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHyperplasia |
| 650 | 0 | 4 |
_aMitomycins _xadministration & dosage |
| 650 | 0 | 4 |
_aMucous Membrane _xpathology |
| 650 | 0 | 4 |
_aNeoplasm Invasiveness _xprevention & control |
| 650 | 0 | 4 | _aPhototherapy |
| 650 | 0 | 4 |
_aProstatectomy _xadverse effects |
| 650 | 0 | 4 |
_aThiotepa _xadministration & dosage |
| 650 | 0 | 4 |
_aUrinary Bladder _xpathology |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aUrine _xanalysis |
| 700 | 1 | _aUtz, D C | |
| 700 | 1 | _aFarrow, G M | |
| 773 | 0 |
_tUrology _gvol. 26 _gno. 4 Suppl _gp. 39-46 |
|
| 999 |
_c3937013 _d3937013 |
||